Celcuity Tumbles 20% as FDA Approval Overshadowed by Launch Delay and Safety Concerns
CELC has more than doubled off its 52-week low of $13.365 on elevated volume (3.3× avg).
Summary
Celcuity shares fell 20% to $88.99 midday Wednesday despite Tuesday's FDA approval of Revtorpyk for HR+/HER2- advanced breast cancer. The selloff follows management's guidance for a late-Q3 launch — a delay from earlier expectations of a pre-PDUFA-ready date — and a label showing higher-than-expected side effects. Stifel analysts flagged the timeline slip and safety profile as negative surprises. The approval itself is a major milestone, but the market is repricing the commercial outlook. With a $4.3B market cap, the 20% drop wipes out roughly $860M in value, reflecting serious concern about the launch ramp. This follows the June 2 detailed data release that also triggered a 25% selloff, suggesting persistent investor skepticism around the drug's competitive profile.
At the time of this announcement, CELC was trading at $88.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $13.37 to $151.02. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.